Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]
Discontinued
Reference number: GID-TA10531
Please note that following on from advice received from the company this appraisal has now been scheduled into the work programme
We anticipate that the appraisal will begin during early February 2021 when we will write to you about how you can get involved.